Pharmacoeconomics and Policy2026，Vol.2Issue(1)：P.19-26,8.DOI:10.1016/j.pharp.2026.02.001
Cost-effectiveness analysis of toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China
Yize Jia 1Shuo Yang 1Shan Zhao 2Shuo Kang3
作者信息
- 1. School of Pharmacy,Hebei Medical University,Shijiazhuang 050017,China
- 2. Department of Oncology,The Second Hospital of Hebei Medical University,Shijiazhuang 050000,China
- 3. Medical Insurance Office,The Second Hospital of Hebei Medical University,Shijiazhuang 050000,China
- 折叠
摘要
关键词
Toripalimab/Bevacizumab/Sorafenib/Hepatocellular carcinoma/Partitioned survival model/Cost‑effectiveness analysis分类
医药卫生引用本文复制引用
Yize Jia,Shuo Yang,Shan Zhao,Shuo Kang..Cost-effectiveness analysis of toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China[J].Pharmacoeconomics and Policy,2026,2(1):P.19-26,8.
